# OnCo record hrr-gene-mutation (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/hrr-gene-mutation/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "hrr-gene-mutation" ;
  schema:name "Homologous recombination repair gene mutation in prostate cancer"@en ;
  schema:alternateName "HRR gene mutation"@en, "HRRm"@en, "HRR-mutated"@en, "homologous recombination repair mutation"@en, "DNA repair gene mutation"@en, "BRCA2 prostate"@en, "ATM prostate"@en, "CDK12 prostate"@en ;
  schema:description "A fault in one of the genes a cell uses to mend broken DNA. It decides whether a PARP inhibitor can be prescribed, but the list of genes that counts is different for each of the four approved routes, and the evidence behind them is mostly evidence about BRCA2."@en ;
  schema:url <https://onco.cc/biomarkers/hrr-gene-mutation/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6fd147f-a77e-4a0b-9280-e82ecc41b4be>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8245a990-3268-4613-b5c5-9537858a1eb9>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0295d202-1cfe-7659-e063-6294a90a476e>, <https://doi.org/10.1056/NEJMoa1603144> ;
  onco:tag "biomarker", "prostate" ;
  onco:related <https://onco.cc/biomarkers/brca-germline/>, <https://onco.cc/biomarkers/brca-somatic/>, <https://onco.cc/biomarkers/hrd-positive/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/>, <https://onco.cc/cancers/prostate-mhspc/> ;
  onco:technologies <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/parp-inhibitor/> ;
  onco:targets <https://onco.cc/targets/brca/>, <https://onco.cc/targets/atm/>, <https://onco.cc/targets/cdk12/>, <https://onco.cc/targets/palb2/>, <https://onco.cc/targets/chek2/>, <https://onco.cc/targets/rad51c/>, <https://onco.cc/targets/rad51d/>, <https://onco.cc/targets/bard1/>, <https://onco.cc/targets/brip1/>, <https://onco.cc/targets/parp/> ;
  onco:drugs <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/rucaparib/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/drugs/talazoparib/> ;
  onco:pathways <https://onco.cc/pathways/homologous-recombination-repair/>, <https://onco.cc/pathways/base-excision-repair-parp/>, <https://onco.cc/pathways/synthetic-lethality-map/>, <https://onco.cc/pathways/ddr/> ;
  onco:terms <https://onco.cc/terms/germline-vs-somatic/>, <https://onco.cc/terms/gbrca-mutation/>, <https://onco.cc/terms/hrd/>, <https://onco.cc/terms/brca-reversion-mutations/>, <https://onco.cc/terms/synthetic-lethality/>, <https://onco.cc/terms/vus/>, <https://onco.cc/terms/castration-resistance/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016/>, <https://onco.cc/key-papers/paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015/>, <https://onco.cc/key-papers/paper-abida-triton2-rucaparib-brca-jco-2020/>, <https://onco.cc/key-papers/paper-quigley-brca2-reversion-cfdna-parp-resistance-cancer-discov-2017/>, <https://onco.cc/key-papers/paper-jensen-clonal-haematopoiesis-cfdna-interference-prostate-jama-oncol-2021/> .